Addex to Present at the Investora Conference
September 23 2020 - 1:00AM
Geneva, Switzerland, September 23,
2020 - Addex Therapeutics Ltd (SIX
and Nasdaq: ADXN), a leading company pioneering allosteric
modulation-based drug discovery and development today announced
that Tim Dyer, Chief Executive Officer, is scheduled to
participate at the Investora Conference taking place in Zurich,
Switzerland on September 23 – September 24, 2020.
In his presentation today, September 23, 2020 at
15:25 - 16:10 CEST, Mr Dyer will provide a corporate update
and recent developments at Addex.
About Addex Therapeutics
Addex Therapeutics is a clinical-stage
pharmaceutical company focused on the development and
commercialization of an emerging class of novel orally available
small molecule drugs known as allosteric modulators for
neurological disorders. Allosteric modulators offer several
potential advantages over conventional non-allosteric molecules and
may offer an improved therapeutic approach to conventional
"orthosteric" small molecule or biological drugs. Addex's
allosteric modulator drug discovery platform targets receptors and
other proteins that are recognized as essential for therapeutic
intervention. Addex's lead drug candidate, dipraglurant (mGlu5
negative allosteric modulator or NAM), is scheduled to enter a
pivotal registration clinical trial for Parkinson’s disease
levodopa induced dyskinesia (PD-LID). In parallel, dipraglurant's
therapeutic use in dystonia is being investigated in preclinical
models. Addex's second clinical program ADX71149 (mGlu2 positive
allosteric modulator or PAM), developed in collaboration with our
partner Janssen Pharmaceuticals, Inc., is scheduled to enter a
Phase 2a proof of concept clinical study for the treatment of
epilepsy. In addition, Addex’s GABAB PAM program has been
licensed to Indivior PLC for the treatment of addiction.
Preclinical programs include GABAB PAM for CMT1A, mGlu7 NAM
for PTSD, mGlu2 NAM for mild neurocognitive disorders, mGlu4 PAM
for Parkinson’s disease and mGlu3 PAM for neurodegenerative
disorders.
Press Contacts:
Tim DyerChief Executive OfficerTelephone: +41 22 884 15
55Email: PR@addextherapeutics.com |
Mike SinclairPartner, Halsin Partners+44 (0)20 7318
2955msinclair@halsin.com |
Forward Looking
StatementsCertain statements made in this announcement are
forward-looking statements including with respect to the creation
of a trading market for ADSs representing the Company's shares
in the United States. These forward-looking statements are not
historical facts but rather are based on the Company's current
expectations, estimates, and projections about its industry; its
beliefs; and assumptions. Words such as 'anticipates,' 'expects,'
'intends,' 'plans,' 'believes,' 'seeks,' 'estimates,' and similar
expressions are intended to identify forward-looking statements.
These statements are not guarantees of future performance and are
subject to known and unknown risks, uncertainties, and other
factors, some of which are beyond the Company's control, are
difficult to predict, and could cause actual results to differ
materially from those expressed or forecasted in the
forward-looking statements. The Company cautions securityholders
and prospective securityholders not to place undue reliance on
these forward-looking statements, which reflect the view of the
Company only as of the date of this announcement. The
forward-looking statements made in this announcement relate only to
events as of the date on which the statements are made. The Company
will not undertake any obligation to release publicly any revisions
or updates to these forward-looking statements to reflect events,
circumstances, or unanticipated events occurring after the date of
this announcement except as required by law or by any appropriate
regulatory authority.
Addex Therapeutics (NASDAQ:ADXN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Addex Therapeutics (NASDAQ:ADXN)
Historical Stock Chart
From Sep 2023 to Sep 2024